胆管癌史上首款靶向药培美替尼闪亮登场！

Intrahepatic cholangiocarcinoma (ICC) is a primary liver cancer with an incidence rate second only to hepatocellular carcinoma (HCC). It originates from intrahepatic secondary and above bile duct epithelial cells and has a worse prognosis than HCC. Radical surgical resection is the preferred treatment for ICC, but its resection rate is only 25%. Especially for cirrhotic patients with obvious liver dysfunction, surgical resection is difficult to perform. Recently, the U.S. Food and Drug Administration officially announced its approval for marketing. Since then, pemetinib, the first targeted drug in the history of cholangiocarcinoma, has made its debut!

The dosage form of pemetinib is tablets, which are available in three specifications. Each tablet contains 4.5 mg, 9 mg, and 13.5 mg of active ingredients. The additives or excipients include magnesium stearate, microcrystalline cellulose, and sodium carboxymethyl starch. The recommended dose of pemetinib is 13.5 mg qd, with 2 weeks of continuous medication followed by 1 week of discontinuation, with a 3-week course of treatment, and continued treatment until disease progression or intolerable toxicity occurs.

The safety and tolerability of pemetinib are generally good in patients with advanced malignant tumors in phase I clinical trials and in patients with locally advanced or metastatic cholangiocarcinoma in phase II clinical trials. Among the 146 patients in the phase II clinical trial, the most common adverse reaction was hyperphosphatemia, with an incidence rate of ≥60% (severity level I-II), which mainly occurred in the early stage of treatment (median time 15 days). Phosphorus-lowering treatment can be carried out through low-phosphorus diet, phosphate binders, diuretics, dose reduction or treatment interruption, and the patient's blood phosphorus level can be measured regularly. Other common adverse reactions (incidence ≥40%) include alopecia, diarrhea, fatigue and dysgeusia.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.